Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA051540 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cambridge Health Alliance | OTHER |
| MaineHealth | OTHER |
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).
This trial is a randomized, six-month study of cannabis (CB) on opioid use that will: (1) evaluate whether adults with chronic, non-cancer pain on COT assigned to CB, compared with those assigned to a waitlist control condition (WL), have greater reduction in opioid dose and/or pain intensity and interference, (2) assess whether participants assigned to CB, compared with those assigned to WL, have improved quality of life, depression, and anxiety; and reduced self-reported opioid dose, (3) evaluate whether those assigned to CB develop symptoms of CUD and have a reduced number of OUD symptoms over the 24-week intervention, as well as at the 12-month time point.
Participants will be randomly assigned to either an active CB arm (n = 60), or to a waitlist control arm (WL) (n = 60). Participants will be assessed at baseline, every 4 weeks for 6 months, and at a 12-month follow-up for opioid use, development of CUD, development or resolution of OUD, and neurocognitive performance. Urine collected will be assessed with quantitative assays.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cannabis (CB) | Experimental | Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
|
| Waitlist (WL) | Active Comparator | Participants assigned to the waitlist control group agreed to delay cannabis use for 24 weeks. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabis | Drug | Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Difference in Prescription Monitoring Program Verified Opioid Dose at Baseline and Week 24 | Median opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day, over monthly interval preceding study visit. | Week 24 |
| Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score Over Post-baseline to Week 24 Interval | The Pain, Enjoyment, General Activity (PEG) scale assesses pain intensity and interference. The scale ranges from 0 to 10, with a higher score indicating greater pain intensity and interference. PEG score was assessed daily through week 24 via daily self-report survey. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Every post-baseline day until week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Difference in Self-Reported Opioid Dose Over Post-baseline to Week 24 Interval | Self-reported opioid dose in morphine milligram equivalents (MME) per day. Self-reported opioid dose was assessed daily through week 24 via daily self-report survey. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Every post-baseline day until week 24 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jodi Gilman, PhD | Massachusetts General Hospital | Principal Investigator |
| A. Eden Evins, MD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maine Medical Center | Portland | Maine | 04102 | United States | ||
| Massachusetts General Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35680252 | Background | Jashinski J, Grossman E, Quaye A, Cather C, Potter K, Schoenfeld DA, Evins AE, Gilman JM. Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol. BMJ Open. 2022 Jun 9;12(6):e064457. doi: 10.1136/bmjopen-2022-064457. |
Not provided
Not provided
All data, code, and materials used in the analyses can be provided by Jodi Gilman and Massachusetts General Hospital pending scientific review and a completed data use agreement/material transfer agreement beginning one year after publication of the results. Requests for all materials should be submitted to Jodi Gilman at jgilman1@mgh.harvard.edu.
Data will become available beginning one year after publication of the results.
Data will be provided pending a scientific review and a completed data use agreement/material transfer agreement. Requests should be submitted to Jodi Gilman at jgilman1@mgh.harvard.edu
Not provided
Not provided
Recruitment took place at three academic medical centers in the Northeastern United States (Massachusetts General Hospital, Boston, MA; Cambridge Health Alliance, Cambridge, MA; Maine Medical Center, Portland, ME).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cannabis (CB) | Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 3, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Prescription Opioid Taper Support (POTS) | Behavioral | All participants were offered weekly group Prescription Opioid Taper Support (POTS) sessions for 24 weeks. POTS is behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering. This intervention was adapted for this trial to include group-based delivery. Sessions are one hour delivered via teleconference and incorporated cognitive behavioral, mindfulness-based, and motivational interviewing strategies. |
|
| Mean Difference in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Summed Score at Weeks 4, 8, 12, 16, 20, 24 | Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form assesses changes in quality of life measures. The scale ranges from 14 - 70, with a lower score indicating greater dissatisfaction with life. Q-LES-SF score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Week 4, week 8, week 12, week 16, week 20, week 24 |
| Mean Difference in PROMIS-29 Depression Subscale Summed Score at Weeks 4, 8, 12, 16, 20, 24 | The 8-item depression subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess depression symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse depression. PROMIS-29 depression subscale score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Week 4, week 8, week 12, week 16, week 20, week 24 |
| Mean Difference in PROMIS-29 Anxiety Subscale Summed Score at Weeks 4, 8, 12, 16, 20, 24 | The 7-item anxiety subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess anxiety symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse anxiety. PROMIS-29 anxiety subscale score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Week 4, week 8, week 12, week 16, week 20, week 24 |
| Mean Difference in Opioid Use Disorder Symptoms at Weeks 4, 8, 12, 16, 20, 24 | Number of opioid use disorder (OUD) symptoms present was assessed via the Diagnostic and Statistical Manual- 5th Edition (DSM-V) checklist. As all participants were taking prescribed opioids under the supervision of a clinician, symptom counts exclude tolerance and withdrawal. Number of symptoms range from 0 to 9. A score of 2 or more indicates a current opioid use disorder diagnosis. Number of opioid use disorder symptoms were assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Week 4, week 8, week 12, week 16, week 20, week 24 |
| Mean Difference in Cannabis Use Disorder Symptoms at Weeks 12 and 24 | Number of cannabis use disorder (CUD) symptoms present was assessed via the Diagnostic and Statistical Manual- 5th Edition (DSM-V) checklist. Number of symptoms range from 0 to 11. A score of 2 or more indicates a current cannabis use disorder diagnosis. The number of cannabis use disorder symptoms were assessed at weeks 12 and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Week 12, Week 24 |
| Boston |
| Massachusetts |
| 02114-2523 |
| United States |
| Cambridge Health Alliance | Cambridge | Massachusetts | 02139 | United States |
| FG001 | Waitlist (WL) | Participants assigned to the waitlist control group agreed to delay cannabis use for 24 weeks. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cannabis (CB) | Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
| BG001 | Waitlist (WL) | Participants assigned to the waitlist control group agreed to delay cannabis use for 24 weeks. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Prescription Monitoring Program-verified daily opioid dose | Median opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day, over monthly interval preceding study visit. | Mean | Standard Deviation | Morphine milligram equivalents (MME)/day |
| ||||||||||||||
| Opioid use disorder (OUD) symptoms | Number of opioid use disorder (OUD) symptoms present at baseline was assessed via the Diagnostic and Statistical Manual- 5th Edition (DSM-V) checklist. As all participants were taking prescribed opioids under the supervision of a clinician, symptom counts exclude tolerance and withdrawal. Number of symptoms range from 0 to 9. A score of 2 or more indicates a current opioid use disorder diagnosis. | Total number of participants analyzed for this baseline measure is 84 due to missing data for two participants in the CB group and one participant in the WL group. | Mean | Standard Deviation | Number of symptoms |
| |||||||||||||
| Pain, Enjoyment, and General Activity (PEG) Scale Score | The Pain, Enjoyment, General Activity (PEG) scale will assess pain intensity and interference. The scale ranges from 0-30, with a higher score indicating greater pain intensity and interference. Collected daily by a self-reported online survey. Individual scores are averaged for each completed daily survey in the 14 days before baseline. | Statistics correspond to analyzed cohort with available baseline data, missing or excluded n=2 (4.8%) in cannabis group and n=9 (20%) in waitlist group. | Mean | Standard Deviation | Score |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Difference in Prescription Monitoring Program Verified Opioid Dose at Baseline and Week 24 | Median opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day, over monthly interval preceding study visit. | Posted | Mean | 95% Confidence Interval | MME/day | Week 24 |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score Over Post-baseline to Week 24 Interval | The Pain, Enjoyment, General Activity (PEG) scale assesses pain intensity and interference. The scale ranges from 0 to 10, with a higher score indicating greater pain intensity and interference. PEG score was assessed daily through week 24 via daily self-report survey. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | One participant from the CB group and eight participants from the WL group were excluded due to them completing less than 14 days of daily surveys. | Posted | Mean | 95% Confidence Interval | score | Every post-baseline day until week 24 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in Self-Reported Opioid Dose Over Post-baseline to Week 24 Interval | Self-reported opioid dose in morphine milligram equivalents (MME) per day. Self-reported opioid dose was assessed daily through week 24 via daily self-report survey. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | One participant from the CB group and eight participants from the WL group were excluded due to not completing at least 14 days of daily surveys. | Posted | Mean | 95% Confidence Interval | MME/day | Every post-baseline day until week 24 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Summed Score at Weeks 4, 8, 12, 16, 20, 24 | Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form assesses changes in quality of life measures. The scale ranges from 14 - 70, with a lower score indicating greater dissatisfaction with life. Q-LES-SF score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Posted | Mean | 95% Confidence Interval | Raw score | Week 4, week 8, week 12, week 16, week 20, week 24 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in PROMIS-29 Depression Subscale Summed Score at Weeks 4, 8, 12, 16, 20, 24 | The 8-item depression subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess depression symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse depression. PROMIS-29 depression subscale score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Posted | Mean | 95% Confidence Interval | score | Week 4, week 8, week 12, week 16, week 20, week 24 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in PROMIS-29 Anxiety Subscale Summed Score at Weeks 4, 8, 12, 16, 20, 24 | The 7-item anxiety subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess anxiety symptoms. The scale uses a t-score metric (mean of 50, SD of 10). Higher scores indicate worse anxiety. PROMIS-29 anxiety subscale score was assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Posted | Mean | 95% Confidence Interval | score | Week 4, week 8, week 12, week 16, week 20, week 24 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in Opioid Use Disorder Symptoms at Weeks 4, 8, 12, 16, 20, 24 | Number of opioid use disorder (OUD) symptoms present was assessed via the Diagnostic and Statistical Manual- 5th Edition (DSM-V) checklist. As all participants were taking prescribed opioids under the supervision of a clinician, symptom counts exclude tolerance and withdrawal. Number of symptoms range from 0 to 9. A score of 2 or more indicates a current opioid use disorder diagnosis. Number of opioid use disorder symptoms were assessed at weeks 4, 8, 12, 16, 20, and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Posted | Mean | 95% Confidence Interval | Number of symptoms | Week 4, week 8, week 12, week 16, week 20, week 24 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Difference in Cannabis Use Disorder Symptoms at Weeks 12 and 24 | Number of cannabis use disorder (CUD) symptoms present was assessed via the Diagnostic and Statistical Manual- 5th Edition (DSM-V) checklist. Number of symptoms range from 0 to 11. A score of 2 or more indicates a current cannabis use disorder diagnosis. The number of cannabis use disorder symptoms were assessed at weeks 12 and 24. From model fit to all post-baseline timepoints, adjusted marginal means at week 24 were computed as a summary measure. | Posted | Mean | 95% Confidence Interval | Number of symptoms | Week 12, Week 24 |
|
From enrollment until end of intervention, up to 24 weeks
Adverse events were systematically assessed at all study visits (Weeks 0, 4, 8, 12, 16, 20 and 24).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cannabis (CB) | Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. | 0 | 42 | 7 | 42 | 36 | 42 |
| EG001 | Waitlist (WL) | Participants assigned to the waitlist control group agreed to delay cannabis use for 24 weeks. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks. | 0 | 45 | 5 | 45 | 35 | 45 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Intrathecal Pump Insertion | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Catheter Blockage | Product Issues | MedDRA 26.0 | Systematic Assessment |
| |
| Cervical disk herniation | Musculoskeletal and connective tissue disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Diabetic ketoacidosis | Metabolism and nutrition disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Dog bite | Injury, poisoning and procedural complications | MedDRA 26.0 | Systematic Assessment |
| |
| Hospitalizations | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment | This serious adverse event term encompasses two inpatient hospitalizations for unspecified abdominal pain and psychiatric distress. |
|
| Hypotension | Vascular disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Knee replacement surgery | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment |
| |
| Opiate withdrawal symptoms | General disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Osteomyelitis (acute) | Infections and infestations | MedDRA 26.0 | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 26.0 | Systematic Assessment |
| |
| Transient ischemic attack | Nervous system disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 26.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pain and discomfort | General disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Anxiety symptoms | Psychiatric disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Non-site specific injuries | Injury, poisoning and procedural complications | MedDRA 26.0 | Systematic Assessment |
| |
| Depressive disorders | Psychiatric disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Musculoskeletal and connective tissue pain and discomfort | Musculoskeletal and connective tissue disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Analgesia supportive care | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment |
| |
| General signs and symptoms | General disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Withdrawal and rebound effects | General disorders | MedDRA 26.0 | Systematic Assessment | Withdrawal and rebound effects from opioid use |
|
| Emotional and mood disturbances | Psychiatric disorders | MedDRA 26.0 | Systematic Assessment |
| |
| General nutritional disorders | Metabolism and nutrition disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA 26.0 | Systematic Assessment |
| |
| Appetite disorders | Metabolism and nutrition disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Bone and joint injuries | Injury, poisoning and procedural complications | MedDRA 26.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Nausea and vomiting symptoms | Gastrointestinal disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Sleep disorders | Psychiatric disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Coronavirus infection | Infections and infestations | MedDRA 26.0 | Systematic Assessment |
| |
| Imaging procedures | Investigations | MedDRA 26.0 | Systematic Assessment |
| |
| Mental impairment (excluding dementia and memory loss) | Nervous system disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Nasal congestion and inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Neurological signs and symptoms | Nervous system disorders | MedDRA 26.0 | Systematic Assessment |
| |
| Therapeutic procedures | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 26.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 26.0 | Systematic Assessment |
| |
| Dental and gingival therapeutic procedures | Surgical and medical procedures | MedDRA 26.0 | Systematic Assessment |
|
Limitations include the reliance on self-reported cannabis use, variability in cannabis products, and potential underpowering to detect small effect sizes.
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jodi Gilman, PhD | Massachusetts General Hospital | 6176437293 | jgilman1@mgh.harvard.edu |
| Apr 20, 2026 |
| Prot_SAP_009.pdf |
| ICF | No | No | Yes | Informed Consent Form | Sep 10, 2025 | Apr 20, 2026 | ICF_010.pdf |
| ID | Term |
|---|---|
| D010146 | Pain |
| D000074609 | Marijuana Use |
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D019966 | Substance-Related Disorders |
| D001523 | Mental Disorders |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C587251 | nabiximols |
Not provided
Not provided
Not provided
|
|
|
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|